Hepion Pharmaceuticals, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 15/100
What the filing says
Item 5.02 filed 2026-07-02 reports departure of directors or officers and/or election of directors and compensatory arrangements. No specific names, dollar amounts, dates of departure, or details of new arrangements are disclosed in the filing header or document index provided. The actual substantive content is not included in the excerpted text.
Why this rating
Filing announces officer/director change but provides no specifics. At $900K market cap, even modest compensation changes matter, but lack of detail prevents assessment of magnitude.
Extracted items
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.